Informace o publikaci

Initiation of first disease-modifying treatment for multiple sclerosis patients in the Czech republic from 2013 to 2016: Data from the national registry ReMuS

Autoři	HORAKOVA D. ROCKOVA P. JIRCIKOVA J. DOLEŽAL Tomáš VACHOVA M. HRADILEK P. VALIS M. SUCHA J. MARTINKOVA A. AMPAPA R. GRUNERMELOVA M. STETKAROVA I. ŠTOURAČ Pavel MARES J. DUFEK Michal KMETOVA E. ADAMKOVA J. HRNCIAROVA T.
Rok publikování	2019
Druh	Článek v odborném periodiku
Časopis / Zdroj	MULTIPLE SCLEROSIS AND RELATED DISORDERS
Fakulta / Pracoviště MU	Lékařská fakulta
Citace
www	http://dx.doi.org/10.1016/j.msard.2019.08.003
Doi	http://dx.doi.org/10.1016/j.msard.2019.08.003
Klíčová slova	Multiple sclerosis; Czech national registry ReMuS; Disease-modifying drugs; Quality of care; Treatment initiation
Popis	Background: : Proper management of multiple sclerosis (MS) requires feedback from clinical practice via registries. Objective: : To introduce the Czech national multiple sclerosis registry, ReMuS, and explore the availability and use of disease-modifying drugs (DMD). Methods: : The analysis focused on patients who started their first DMD, either with first-line or second-line medication and was based on reimbursement criteria set by Czech regulators. Baseline information was used to predict relapses after DMD initiation and to compare patients that started DMD in different years. Results: : A total of 3,328 patients started DMD treatment for MS between 2013 and 2016; 3,203 on first-line and 125 on second-line medication. The proportion of patients starting on second-line drugs increased from 1.8% in 2013 to 4.7% in 2016. The occurrence of a relapse within one year of DMD initiation was significantly related to (1) the Expanded Disability Status Scale (EDSS) score immediately prior to starting DMD and (2) the number of previous relapses. Both parameters were significantly lower in patients starting in later years of the explored interval. Conclusion: : Data from the ReMuS registry highlights improvements made in the management of MS in the Czech Republic. However, a relatively low percentage of patients started treatment using second-line drugs, in contrast to trends in other countries.